Beyond Semaglutide
The metabolic drug revolution isn't stopping at semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Two next-generation compounds — retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors) and orforglipron (the first oral GLP-1 agonist) — are in late-stage development with potential launches approaching. For men on TRT, these drugs may offer even better synergy for body composition optimization than current options. Here's what we know and what's still speculative.
Current GLP-1 receptor agonists like semaglutide and tirzepatide have already reshaped the metabolic landscape. Our GLP-1 and TRT guide covers how these drugs complement testosterone therapy for body composition. But the pipeline is advancing rapidly, and the next generation of metabolic drugs promises even greater efficacy.
Retatrutide: The Triple Agonist
Retatrutide is Eli Lilly's investigational triple hormone receptor agonist, targeting three metabolic pathways simultaneously:
- GLP-1 receptor: Reduces appetite, slows gastric emptying (same mechanism as semaglutide)
- GIP receptor: Enhances insulin secretion, may improve fat metabolism (same addition as tirzepatide)
- Glucagon receptor: The new addition — stimulates hepatic fat oxidation, increases energy expenditure, and may preserve lean mass during weight loss
Phase 2 trial results were striking: participants receiving the highest dose of retatrutide lost an average of 24.2% of body weight over 48 weeks. For context, semaglutide achieves approximately 15% weight loss, and tirzepatide reaches approximately 20%. The glucagon receptor component appears to drive the additional efficacy.
Phase 3 trial readouts are expected in H1 2026. If results hold, retatrutide could become the most potent metabolic drug ever approved.
Orforglipron: The First Oral GLP-1
Orforglipron (also Eli Lilly) is a non-peptide oral GLP-1 receptor agonist — meaning it's a pill rather than an injection. This is significant because all current GLP-1 drugs require subcutaneous injection (weekly for semaglutide/tirzepatide).
Phase 2 data showed orforglipron produced weight loss of approximately 9–14% over 36 weeks, with favorable metabolic improvements in glucose and lipid markers. While less potent than injectable options, the convenience of a daily pill could dramatically expand the patient population willing to use metabolic drugs.
For TRT patients already comfortable with injections, oral GLP-1 may not represent a major convenience upgrade. But for men who are on topical testosterone (creams) and want to avoid needles entirely, an oral metabolic drug completes an entirely injection-free optimization protocol.
Why This Matters for TRT
The synergy between TRT and metabolic drugs operates on multiple levels:
- Breaking the metabolic cycle: Low testosterone and insulin resistance form a vicious cycle. GLP-1 drugs attack the metabolic side (reducing insulin resistance, visceral fat) while TRT attacks the hormonal side. Together, they break the cycle from both directions simultaneously.
- Body composition optimization: GLP-1 drugs reduce fat mass. TRT preserves and builds lean mass. The combination produces significantly better body composition outcomes than either alone.
- Testosterone restoration: Substantial weight loss from GLP-1 drugs can actually raise endogenous testosterone — approximately 1 ng/dL per point of BMI reduction. For some men, aggressive metabolic intervention may reduce or eliminate the need for TRT.
The Muscle Preservation Question
One of the biggest concerns with GLP-1 drugs is muscle loss. Rapid weight loss from any cause — caloric restriction, bariatric surgery, or GLP-1 therapy — typically includes some lean mass loss alongside fat loss. Studies suggest approximately 25–40% of weight lost on GLP-1 drugs is lean tissue.
This is where TRT provides a critical protective effect. Testosterone's anabolic properties directly counteract the muscle-wasting tendency of aggressive caloric deficit. Men on TRT who use GLP-1 drugs are likely to preserve substantially more lean mass during weight loss than men without testosterone support — though specific combination trial data is still limited.
Retatrutide's glucagon receptor component is particularly interesting here. Glucagon stimulates hepatic fat oxidation preferentially, which may shift the weight loss composition toward more fat and less muscle. If confirmed in Phase 3 trials, this would make retatrutide an even better partner for TRT-based body composition protocols.
What to Watch For
- Retatrutide Phase 3 readouts (H1 2026): Will the 24% weight loss hold in larger populations? What's the lean mass preservation profile?
- Orforglipron approval timeline: If approved, the first oral GLP-1 could launch in 2026–2027
- Combination protocol data: Formal studies of TRT + next-gen metabolic drugs would be extremely valuable but are unlikely to happen soon. Most evidence will come from clinical practice and patient-reported outcomes.
- Compounding access: Current GLP-1 drugs have been available through compounding pharmacies at reduced cost. The SAFE Drugs Act could restrict this for new drugs — potentially limiting affordable access.
The metabolic drug revolution and the TRT optimization movement are converging. For men dealing with both low testosterone and metabolic dysfunction — which is a very large population — the combination of hormonal and metabolic intervention represents a genuinely transformative approach to health.
For current GLP-1 and TRT guidance, see our complete GLP-1 + TRT guide. For clinics offering metabolic + hormone protocols, check our clinic reviews.